Clinical trials: Neoadjuvant Radiotherapy
Cancer of Pancreas, Cancer of the Pancreas
Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
The purpose of this study is to determine whether using FOLFIRINOX chemotherapy and Stereotactic Body Radiation Therapy (SBRT) prior to surgery in patients with pancreatic cancer is safe and well tolerated.
- Conditions
- Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer
- Trial name
- NCT01446458
- Testing
- Modified FOLFIRINOX, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Emory University
Rectal Cancer
Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)
Colorectal cancer is a common gastrointestinal tumor, with rising incidence in China. Rectal cancer accounts for nearly half of new cases, and many patients are diagnosed at a locally advanced stage.
- Trial name
- PUCRT (NCT06770270)
- Testing
- Pucotenlimab
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Rectal Cancer
A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer
A multicenter single-arm phase 2 study to evaluate safety and efficacy of the total neoadjuvant therapy of short course radiation therapy followed by neoadjuvant oxaliplatin/fluorouracil-based chemotherapy (CAPOX) for cT2 rectal…
- Trial name
- AMBITION (NCT05939661)
- Testing
- Radiation, Chemotherapy, Surgery
- Where
- 2 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Osaka University
Stage III Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma
Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Stage III Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage IVA Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma
- Trial name
- NCT00017160
- Testing
- doxorubicin, filgrastim, ifosfamide
- Where
- 235 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Glioblastoma Multiforme
PreOperative Brain Irradiation in Glioblastoma
PreOperative Brain Irradiation in Glioblastoma (POBIG) is a phase I study that will test the safety and feasibility of a single fraction of preoperative radiotherapy in patients with a new radiological diagnosis of glioblastoma…
- Trial name
- POBIG (NCT03582514)
- Testing
- Preoperative brain irradiation (single fraction)
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- The Christie NHS Foundation Trust
Rectal Cancer, Quality of Life
Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer
Observational study to evaluate longitudinal quality of life according to standardized EORTC questionaires as well as functional Outcome, oncological outcome and toxicity in patients treated with neoadjuvant short term radiation…
- Conditions
- Rectal Cancer, Quality of Life, Radiation Therapy, Chemoradiation
- Trial name
- NEOCARE (NCT03731130)
- Testing
- EORTC QLQ C30, EORTC QLQ CR29
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Colon Cancer, Rectal Cancer
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
The purpose of this study is to find out how well patients with cancer of the rectum do if they get all of their other treatment - chemotherapy by itself followed by chemotherapy and radiation together - before surgery.
- Trial name
- NCT01363843
- Testing
- FOLFOX6, RT with concurrent chemotherapy, Surgery
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- William Sikov MD
Rectal Cancer
Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer
This study is designed to test the efficacy and safety of total neoadjuvant induction and consolidation CapeOX plus neoadjuvant intensity modulated radiotherapy with concurrent capecitabine for MRI defined high-risk rectal cancer.
- Trial name
- NCT02864849
- Testing
- Oxaliplatin, Capecitabine, Intensity modulated radiotherapy
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Peking University Cancer Hospital & Institute
Resectable Pancreatic Cancer
Borderline Pancreas Study: FOLFIRINOX +SBRT
Primary Objective: To determine the rate of downstaging to resectability in patients with borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative therapy. Secondary Objective(s): 1.
- Trial name
- GCC 1324 (NCT01992705)
- Testing
- Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable, -Oxaliplatin 85 mg/m2 IV on Day 1, -Irinotecan 180 mg/m2 IV on Day 1
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Maryland, Baltimore
Locally Advanced Rectal Cancer
Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
phase II clinical trial to evaluate node-sparing short-course radiation combined with total neoadjuvant CAPOX and Sintilimab for MSS locally advanced rectal cancers.
- Trial name
- CASINOs (NCT06204094)
- Testing
- node-sparing short-course radiotherapy, Sintilimab, Capecitabine
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Jinhua Central Hospital
Malignant Tumor of Lacrimal Drainage Structure
Neoadjuvant Radiotherapy for Malignant Lacrimal Sac Tumors
The treatment for malignant lacrimal sac tumors is difficult and the prognosis is poor. The conventional strategy is surgical resection followed by adjuvant radiotherapy with or without concurrent chemotherapy.
- Trial name
- NCT04016675
- Testing
- Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery, Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Prostate Adenocarcinoma
Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device as a neo-adjuvant therapy in men with prostate cancer
- Trial name
- NCT04543903
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- 3 sites in Israel
- Volunteers
- 1 people
- Sponsor
- Alpha Tau Medical LTD.
Small-cell Lung Cancer
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
This is a non-randomized, open-label, single-center, phase II trial to evaluate the safety and effectiveness of surgery or radiotherapy after PD-L1 inhibitor (TQB2450) and chemotherapy induction therapy followed by maintenance…
- Trial name
- NCT04539977
- Testing
- TQB2450
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Locally Advanced Soft Tissue Sarcoma
Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas
This is a multi-center, multi-arm open-label phase Ib/II clinical study assessing the efficacy of concurrent lurbinectedin in combination with radiotherapy in patients with locally advanced, resectable, high-grade sarcomas.
- Trial name
- NCT06217536
- Testing
- Lurbinectedin, Radiotherapy, Non-investigational surgery
- Sponsor
- University of California, San Francisco
Rectal Cancer
Lateral Lymph Node Dissection After Neoadjuvant Chemo-radiation in Advanced Low Rectal Cancer
Lateral lymph nodes (LLD) metastasis is a major cause of local recurrence for advanced rectal cancer. As for the treatment strategies on LLN metastasis, there are huge controversies on whether lateral pelvic lymph nodes…
- Trial name
- NCT02614157
- Testing
- LLND, labeled line
- Where
- China
- Volunteers
- 51 people
- Sponsor
- West China Hospital
Breast Cancer
Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop tumor cells from dividing so…
- Trial name
- NCT00082641
- Testing
- autologous dendritic cell-adenovirus p53 vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Nebraska
Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer
Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer
Background: Fewer than 10 percent of people with pancreas cancer can have surgery. Surgery gives the best outcome. Radiation therapy is usually used to make surgery possible. But it does not work for most people.
- Conditions
- Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Cancer
- Trial name
- NCT04327986
- Testing
- M7824, M9241, SBRT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer Stage II, Rectal Cancer Stage III
Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer
This is a multicenter, single-arm, phase II study of nivolumab in combination with regorafenib in subjects with locally-advanced rectal cancer who are eligible for a curative treatment including pre-operative SCRT and TME(or…
- Trial name
- REGINA (NCT04503694)
- Testing
- Nivolumab 10 MG/ML Intravenous Solution, Regorafenib 30 MG Oral Tablet, Radiotherapy
- Where
- 9 sites in Belgium
- Volunteers
- 72 people
- Sponsor
- Jules Bordet Institute
Pancreatic Adenocarcinoma
Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer
This is a Phase II open study, not randomized with a neoadjuvant therapy,combination of Gemcitabine (1,000 mg/m2/week) with Erlotinib (100mg/day) (3 cycles of 4 weeks), followed by gemcitabine (300 mg/m2/week) combined with…
- Trial name
- GEMCAD1003 (NCT01389440)
- Testing
- Gemcitabine and Erlotinib
- Where
- 10 sites in Spain
- Volunteers
- 24 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
HER2-Negative Locally Advanced Breast Cancer
Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer
A Prospective, Multicenter, Randomized Controlled Phase II Study to Evaluate the Efficacy and Safety of Adebrelimab Combined with Chemotherapy with or without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally…
- Trial name
- NCT06908668
- Testing
- Neoadjuvant Chemotherapy Combined with Immunotherapy and Radiotherapy, Neoadjuvant Chemotherapy Combined with Immunotherapy
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences